Akorn, Inc. AKRX and Hi-Tech Pharmacal Co., Inc. HITK today announced that they have entered into a definitive agreement
under which Akorn will acquire Hi-Tech for $640 million in cash.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing
and marketing generic and branded prescription and over-the-counter
(OTC) products. Hi-Tech specializes in difficult to manufacture liquid
and semi-solid dosage forms and produces and markets a range of oral
solutions and suspensions, as well as topical ointments and creams,
nasal sprays, otics, sterile ophthalmics and sterile ointment and gels
products. Hi-Tech's Health Care Products division is a leading developer
and marketer of OTC products. Hi-Tech's ECR Pharmaceuticals subsidiary
markets branded prescription products.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in